US equities |
NVDA $235.09 ▲+1.83% MU $1,075.51 ▼-1.99% TSLA $373.49 ▲+5.47% SPCX $157.14 ▲+6.13% SNDK $1,717.59 ▼-3.92% AMD $635.46 ▲+3.20% STX $805.43 ▼-14.82% INTC $122.16 ▲+1.80%
FinancialContent

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

8.970 +0.060 (+0.67%)
Delayed Quote Updated: 11:18 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Is Xilio Therapeutics (XLO) Stock up 168% Today? ↗
Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead. 
Via InvestorPlace
News headline image
US Stocks Flat; Initial Jobless Claims Fall To 210,000 ↗
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
Martin Huber, M.D., to leave Xilio Therapeutics and remain an advisor 
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at Upcoming Investor Conferences
From Xilio Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >